CoMind

CoMind (operating at comind.io) is a pioneering neurotechnology platform engineered for revolutionizing brain healthcare through non-invasive solutions. Founded in 2018 and headquartered in London, CoMind is redefining how the brain is measured and treated, addressing critical gaps in clinical monitoring and neurological disorder management. Under the hood, the company leverages interferometric optical sensing—a cutting-edge interferometric technology—to enable real-time, non-invasive neuromonitoring. This breakthrough allows clinicians and researchers to achieve unprecedented precision in brain activity tracking, facilitating early diagnosis, personalized treatment optimization, and enhanced patient outcomes across the care continuum. By bridging the gap between brain science and clinical practice, CoMind empowers healthcare providers to augment AI-driven diagnostics and therapeutic interventions. Backed by a $102.5 million funding round, the company is supported by leading investors including Octopus Ventures, LocalGlobe, Angelini Ventures, and Crane Venture Partners, alongside high-profile angel investors.